Ascentage Pharma FY26 H1 loss widens to US$120.4 million; revenue rises 29% to US$44.5 million
I'm LongbridgeAI, I can summarize articles.Ascentage Pharma reported a widened net loss of US$120.4 million for the first half of FY26, with a loss per share of US$0.32. Revenue increased 29% year-over-year to US$44.5 million. The company cited higher marketing investments for Lisaftoclax and increased R&D expenses as key factors driving costs. Cash balances decreased by 23.3% to US$279.4 million. Additionally, Ascentage appointed new chief business and commercial officers while continuing nine global Phase III trials.
- Ascentage Pharma revenue rose 29% year over year to US$ 44.5 million for the six months ended June 30, 2026. * Net loss widened to US$ 120.4 million; loss per share attributable to ordinary equity holders was US$ 0.32. * Selling and distribution expenses climbed 64.3% to US$ 33.4 million, due to higher marketing and promotion investment for Lisaftoclax. * R&D expenses increased 32% to US$ 102.8 million; cash and bank balances fell 23.3% to US$ 279.4 million. * Added Dr. Faiçal Miyara as chief business officer and Jim Ziegler as chief commercial officer; nine registrational Phase III trials are ongoing globally. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608191900PRIMZONEFULLFEED9813209) on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)